Liposomal anthracycline administration and toxicity management: a nursing perspective
- PMID: 15717743
- DOI: 10.1053/j.seminoncol.2004.08.007
Liposomal anthracycline administration and toxicity management: a nursing perspective
Abstract
Nursing care of the patient receiving chemotherapy includes patient education and drug administration, as well as ongoing assessment, early identification, and intervention for side effects. Two liposomal anthracyclines are available in the United States, pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) and liposomal daunorubicin (DaunoXome [DNX]). Because of their unique liposomal formulations, the administration and toxicity profiles of these agents are different from those of conventional anthracyclines, as well as each other. Common severe toxicities of conventional anthracycline treatment such as nausea/vomiting, alopecia, and neutropenia are less frequent and less severe during liposomal anthracycline treatment, and cumulative-dose cardiotoxicity is rare, particularly with PLD therapy. Dose-related adverse events with liposomal anthracycline therapy include stomatitis and neutropenia, and more frequent doses of PLD are associated with hand-foot syndrome. Ongoing nursing assessment, patient education, and adjustments to the dose or dose-schedule can reduce the severity or frequency of these toxicities. Nurses must be aware of the unique characteristics of liposomal anthracycline therapy to provide optimal patient education and nursing care.
Similar articles
-
Cardiac safety of liposomal anthracyclines.Semin Oncol. 2004 Dec;31(6 Suppl 13):161-81. doi: 10.1053/j.seminoncol.2004.08.006. Semin Oncol. 2004. PMID: 15717742 Review.
-
Pharmacoeconomics of liposomal anthracycline therapy.Semin Oncol. 2004 Dec;31(6 Suppl 13):191-5. doi: 10.1053/j.seminoncol.2004.08.008. Semin Oncol. 2004. PMID: 15717744 Review.
-
Use of liposomal anthracyclines in Kaposi's sarcoma.Semin Oncol. 2004 Dec;31(6 Suppl 13):36-52. doi: 10.1053/j.seminoncol.2004.08.003. Semin Oncol. 2004. PMID: 15717737 Review.
-
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90. doi: 10.1053/j.seminoncol.2004.08.010. Semin Oncol. 2004. PMID: 15717738 Review.
-
Role of liposomal anthracyclines in the treatment of multiple myeloma.Semin Oncol. 2004 Dec;31(6 Suppl 13):147-60. doi: 10.1053/j.seminoncol.2004.08.005. Semin Oncol. 2004. PMID: 15717741 Review.
Cited by
-
Novel therapeutic approaches in pediatric and young adult sarcomas.Curr Oncol Rep. 2006 Jul;8(4):310-5. doi: 10.1007/s11912-006-0038-0. Curr Oncol Rep. 2006. PMID: 17254532 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources